Until legislation regulates access to medicines awaiting reimbursement, or decision times are reduced, implementing robust local procedures is essential to guarantee fair and equitable MSS access, particularly for patients requiring treatment before national PR resolution.
Porcel‐Maleno et al. (2026) studied this question.